Literature DB >> 25371481

Is aspartate aminotransferase-to-platelet ratio index a biomarker in the evaluation of advanced fibrosis in non-alcoholic fatty liver disease?

Mehmet Agilli1, Fevzi Nuri Aydin2, Tuncer Cayci2, Yasemin Gulcan Kurt2.   

Abstract

Entities:  

Year:  2014        PMID: 25371481      PMCID: PMC4219149          DOI: 10.1093/gastro/gou063

Source DB:  PubMed          Journal:  Gastroenterol Rep (Oxf)


× No keyword cloud information.
Dear Editor, We read with great interest the recent article by Tapper et al. [1]. The authors aimed to determine the clinical predictors of advanced histology in the referral population. In multivariate logistic regression analyses, they have demonstrated that body mass index (BMI) ≥30 kg/m2, female gender, and aspartate aminotransferase (AST) >40 IU/L were associated with a non-alcoholic fatty liver disease (NAFLD) activity score >4. They have also shown that AST-to-platelet ratio index (APRI) >1 was the most significant predictor of advanced fibrosis. Additionally, they have suggested that patients with suspected NAFLD should be routinely evaluated for advanced liver disease, including non-invasive indices of fibrosis such as APRI, and serious consideration given to liver biopsy. Understanding the value of non-invasive indices of fibrosis such as APRI in patients with NAFLD, we consider this large, retrospective study to be very important; however, we have some questions that should be mentioned as contributory factors. The authors mentioned exclusion criteria: patients with viral hepatitis, alcoholic liver disease, haemochromatosis, Wilson disease, drug-induced liver injury and autoimmune hepatitis were excluded from the study. We wonder whether patients with pancreatobiliary disease and platelet disorders were also excluded from the study. Elevated AST levels might be the result of the pancreatobiliary disease, even in the absence of obvious liver disease [2]. Therefore, amylase, alkaline phosphatase, gamma-glutamyl transferase, bilirubin results and platelet count should also be included in this study. APRI has an important disadvantage because of the use of upper limits of normal (ULN) for aminotransferases. There is no standardization between laboratories [3]. It was shown that ULN for AST ranged from 26–49 IU/L according to gender, BMI and serum cholesterol in the control population [4]. On the other hand, in another study, it was reported that serum aminotransferase activities were significantly higher in men than in women in a control population [5]. In conclusion, we think APRI results could cause confusing interpretations for the staging of advanced fibrosis in the patients with NAFLD. We need further studies to better understand the relationship between APRI results and fibrosis in patients with NAFLD.
  5 in total

1.  Prognosis value of the blood transaminase in acute ischaemic stroke: gender factors should be considered.

Authors:  Wen-Jun Tu; Hui Chen
Journal:  Clin Sci (Lond)       Date:  2012-03       Impact factor: 6.124

2.  FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C.

Authors:  Rachel Morra; Pascal Lebray; Patrick Ingiliz; Yen Ngo; Mona Munteanu; Vlad Ratziu; Thierry Poynard
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

3.  Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

Authors:  Hugo Perazzo; Raluca Pais; Mona Munteanu; Yen Ngo; Denis Monneret; Françoise Imbert-Bismut; Joseph Moussalli; Pascal Lebray; Yves Benhamou; Dominique Thabut; Vlad Ratziu; Victor de Ledhingen; Thierry Poynard
Journal:  Clin Res Hepatol Gastroenterol       Date:  2014-06-09       Impact factor: 2.947

4.  Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase.

Authors:  Hui-Min Xu; Yan Chen; Jie Xu; Quan Zhou
Journal:  World J Gastroenterol       Date:  2012-11-07       Impact factor: 5.742

5.  Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease.

Authors:  Elliot B Tapper; Katherine Krajewski; Michelle Lai; Tracy Challies; Robert Kane; Nezam Afdhal; Daryl Lau
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-07-07
  5 in total
  1 in total

Review 1.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.